Business Of Biotech – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

Business Of Biotech

Ben Comer

Business

Science

Frequency: 1 episode/7d. Total Eps: 320

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.

Read moreCollapse

Site

RSS

Apple

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

🇬🇧 Great Britain - management
12/08/2026
#51
🇬🇧 Great Britain - management
08/08/2026
#70
🇬🇧 Great Britain - management
29/07/2026
#94
🇬🇧 Great Britain - management
18/07/2026
#88

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 48%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Funding Tips And Moving From R&D To Commercial With Madrigal Pharmaceuticals' Mardi Dier

Episode 279

Monday, November 10, 2025 • Duration 46:11

We love to hear from our listeners. Send us a message.

On this week's episode of the Business of Biotech, Mardi Dier, CFO at Madrigal Pharmaceuticals, talks about building relationships in investment banking and investor relations before moving into business development and becoming a chief financial officer. Mardi describes how drug companies transition from an R&D focus to commercializing products, how to read IPO windows and manage expectations, pricing new drugs, and balancing commercial efforts with pipeline renewal and maintenance.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Read moreCollapse

Emerging From Stealth With Vima Therapeutics' Bernard Ravina, M.D.

Episode 278

Monday, November 3, 2025 • Duration 42:48

We love to hear from our listeners. Send us a message.

On this week's episode of the Business of Biotech, we're speaking with Bernard Ravina, M.D., CEO at Vima Therapeutics, a company that emerged from stealth in May with $60 million Series A financing to develop an oral candidate for dystonia, a movement disorder. Ravina talks about transitioning from government and academic medicine to industry, partnering with Atlas Ventures and defining the company's thesis, the reasons behind working in stealth mode and when to emerge, and the clinical plan and potential for VIM0423.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Read moreCollapse

Improving Cardiovascular Outcomes With Immediate Therapeutics' Atul Deshpande, Ph.D.

Episode 269

Monday, September 1, 2025 • Duration 01:04:36

We love to hear from our listeners. Send us a message.

On this week's episode, Atul Deshpande, Ph.D., CEO at Immediate Therapeutics, talks about partnering with American cities to conduct clinical trials during ambulance rides to the hospital, with the goal of preserving heart function and reducing mortality related to acute cardiovascular events, including heart attacks. Deshpande reflects on his previous experience developing and commercializing Dupixent at Sanofi, describes the history and mechanism of Immediate's glucose-insulin-potassium (GIK) candidate, IMT-358, and explains why there is more to intellectual property than just patents.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Read moreCollapse

Public Sector Forged, Private Sector Tested with Renovaro BioSciences' Mark Dybul, M.D.

Monday, December 11, 2023 • Duration 01:03:40

We love to hear from our listeners. Send us a message.

During his leadership of the President's Emergency Plan for AIDS Relief during the George W. Bush administraion, Dr. Mark Dybul, M.D. shepherded programs credited with saving more than 25 million lives. For many years after that public service drew to a close, he continued the mission as executive director of The Global Fund to Fight AIDS, Tuberculosis and Malaria--working in lockstep with not only the world's leading scientists, but the likes of Bono and Sir Elton John along the way.
But, it wasn't all glamor and heroics. Dybul had to influence some decidedly conservative global political machines of the importance of addressing the AIDS epidemic, particularly, at the time, in Africa. He had to fight through federal and global beuracracies for every dime of funding earned. His leadership required resolve in the face of complexity and adversity.
Nothing could have better prepared him for biotech leadership, which has dealt Dr. Dybul an unfair share of unique adversity that's, quite frankly, the stuff of a Dateline NBC episode. On this epsiode of the Business of Biotech podcast, Dybul, CEO at Renovaro Biosciences, gets introspective on leadership forged in the fires of public service and battle-tested in the private sector.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

mRNA Vaccine Platforms with Combined Therapeutics' Dr. Romain Micol

Monday, December 4, 2023 • Duration 28:13

We love to hear from our listeners. Send us a message.

Combined Therapeutics President & CEO Dr. Romain Micol is operating his company in a very noisy space, where hundreds of new biotechs have popped up on the coattails of a COVID-driven renewal of interest in mRNA vaccines. Micol recognizes that noise and the competition it brings for capital and mindshare. He's not only aware of it — he welcomes it. On this quick episode of the Business of Biotech podcast, Micol shares the unique approach Combined Tx is taking to distinguishing itself in the mRNA infectious disease and cancer vaccine space, from the delivery, safety, efficay, and business perspectives.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Read moreCollapse

Biotech Dealmaking with Regeneron's Nouhad Husseini

Monday, November 27, 2023 • Duration 01:02:44

We love to hear from our listeners. Send us a message.

When it comes to landing and executing strategic partnerships, Regeneron puts on a clinic. Partnerships, acquisitions, licensing agreements, and other deals large and small with Intellia, Decibel Therapeutics, BARDA, Alnylam, and Sonoma Therapeutics are just a sampling of those making news this year alone. The man behind much of that dealmaking is none other than Nouhad Husseini, SVP and Head of Business Development and Corporate Strategy at Regeneron. He’s a guy who’s deftly married the art and science of biopharma dealmaking, and on this episode of the Business of Biotech podcast, we’re getting introspective with this legend in the making, who our friend Allan Shaw says “turns the deals he touches into gold.” Strategic dealmaking is central to the biotech business, and today’s episode offers a master class.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Read moreCollapse

Backpacks And Biotech with Luke Timmerman

Monday, November 20, 2023 • Duration 54:08

We love to hear from our listeners. Send us a message.

From his vantage point as an independent biotech journalist, Luke Timmerman has been watching the expansions and retractions of the industry for a couple of decades now. His unique perspective is hard to equal, and that perspective is, despite tough markets and tepid public sentiment, decidedly bullish. Luke's optimism is fed by sound logic gained from a career spent in observation mode, watching the development of purpose-built tools matched to address the fragility of human biology.
Luke's tireless advocacy for the industry also stretches well beyond his professional coverage and punditry. Through his Timmerman Traverse initiative, he's figured out a way to weave his personal and professional passions into a tapestery that serves some of the philanthropic initiatives our industry cares about most. On this episode of the Business of Biotech, we'll get to know Luke personally, we'll learn about his philanthropic work, and we'll give you a healthy dose of optimism as we look ahead to the next decade in biotech.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Read moreCollapse

RNA Delivery Business with Liberate's Shawn Davis, Ph.D. & Walter Strapps, Ph.D.

Monday, November 13, 2023 • Duration 54:40

We love to hear from our listeners. Send us a message.

Earlier this year, Shawn Davis, Ph.D. left a pretty comfortable position at AstraZeneca (and Amgen before that, and Milliken, and others, before that) to lead Liberate Bio. He brought along another industry notable in Merck/Intellia alumnus Walter Strapps, Ph.D., who serves as CSO at Liberate. Why'd they do it? Because RNA delivery is such a crucial step toward revolutionary genetic medicine, but it's tough science. They think they can change that. On this episode of the Business of Biotech, Drs. Davis and Strapps share how they're applying automation and machine learning technologies to minimize the challenges associated with targeted delivery of genetic medicine and overcome the limitations of AAV. During our conversation, they both leaned hard into how their previous experiences have shaped the work they're doing, and the wide-open business opportunities Liberate Bio is creating.

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Read moreCollapse

The Legendary Steve Gorlin's Golden Rules

Monday, November 6, 2023 • Duration 57:48

We love to hear from our listeners. Send us a message.

Shortly after Thalidomide became a household word—albeit a very, very bad one—a biotech investor bought it for a couple hundred grand. Who on earth would want a drug pulled from the market for causing birth defects? Steve Gorlin did.

Today, Thalidomide is the foundation of cancer drugs worth billions of dollars. Gorlin doesnt own it anymore, but the story of how he got it is just one of the experiences that contributed to the codification of his "golden rules." Following those rules has paid off. SIx of the companies he's founded acieved valuations, or sold, for more than $1 billion each. This week, the Business of Biotech sits down with the legendary biotech investor Steve Gorlin, now CEO of CoRegen, for a conversation on his golden rules for picking winners.

Gear up for an action-packed, LIVE, and INTERACTIVE Business of Biotech as we delve into the nitty-gritty of IP and legal considerations crucial for budding biotech entities. Get your queries resolved straight from a seasoned professional, minus the lawyer's fees! YOU HAVE TO REGISTER FOR THIS ONE (no cost), so head to tinyurl.com/boblive23, or secure your spot for Business of Biotech Live! Legal & IP Protection For New Biotechs here. Join us on Monday, November 13th, at 11 am Eastern. You don't want to miss this!

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

UPCOMING SPECIAL: Unraveling Biotech's Legal Enigmas With Keir LoIacono

Wednesday, November 1, 2023 • Duration 02:13

We love to hear from our listeners. Send us a message.

Register for Business of Biotech Live! Legal & IP Protection For New Biotechs here. Get ready to unravel the legal enigmas of the biotech world with me and Keir LoIacono, Esq. The CEO of Blue Sphere Bio, Keir is no stranger to high-stakes decision-making and legal conundrums in the biotech industry. Having served as the general counsel and VP of Corporate Development for Oncosec, lead in-house counsel and senior director for Advaxis, and intellectual property attorney at the leading biotech law firm Lerner, David, Littenberg, Krumholz, and Mentlick, Keir is a powerhouse of knowledge ready to share his insights.

Gear up for an action-packed, LIVE, and INTERACTIVE Business of Biotech as we delve into the nitty-gritty of IP and legal considerations crucial for budding biotech entities. Get your queries resolved straight from a seasoned professional, minus the lawyer's fees! YOU HAVE TO REGISTER FOR THIS ONE (no cost), so head to tinyurl.com/boblive23, or secure your spot for Business of Biotech Live! Legal & IP Protection For New Biotechs here. Join us on Monday, November 13th, at 11 am Eastern. You don't want to miss this!

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Business Of Biotech – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Business Of Biotech – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Shared links between episodes and podcasts

Other70

LinkedIn4

Buzzsprout2

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Other70

LinkedIn4

Buzzsprout2